Visual Improvement in Retinal Vein Occlusion Patient Who Had Intravitreal Bevacizumab with and without Laser Photocoagulation
Article Sidebar
Abstract
Background: Intravitreal bevacizumab (IVB) appears to be an effective and safe drug for reducing macular edema and improving visual acuity secondary to RVO. Grid photocoagulation to macular edema caused by BRVO significantly improved long-term visual prognosis. In CRVO, reduced the angiographic evidence of macular edema, but did not lead to improvement in the vision of treated eyes.
Methods: an observational, retrospective study from medical record of patients RVO underwent IVB and combined treatment at Cicendo National Eye Center conducted between January and December 2012. A total of 49 eyes from 49 patients met the inclusion criteria. Data was compiled on demographic characteristics, pre and postoperative visual acuities. The main outcome was proportion of visual gain in 1 month after therapy.
Result: All patients (49 eyes) completed the 1 months follow-up with 17 patients BRVO who had treatment IVB and 11 patients with combined treatment. And 14 patients CRVO who had treatment IVB and 7 patients had combined treatment. The proportion of BRVO and CRVO eyes have the same visual improvement in IVB and combined treatment groups (BRVO 58.8% vs 72.7%, p=0.120 and CRVO 57.1% vs 57.1%, p=1.000).
Conclusion: There was no significant difference in the proportion of visual improvement between IVB and combined treatment groups in BRVO and CRVO at one months follow up.
Keywords: branch retinal vein occlusion, central retinal vein occlusion, intravitreal bevacizumab, laser photocoagulation
Full text article
References
Rehak M. Wiedeman P. Retinal vein thrombosis: pathogenesis and management. Germany. International Society on thrombosis and haemostasis. 2010
Channa R, Smith M, Campochiaro P. A. Treatment of macular edema due to retinal vein occlusions. USA. Clinical ophtalmology 2011;5:705-713
Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N. Grid Photocoagulation combined with intravitreal bevacizumab for reccurent macular edema associated with retinal vein occlusion. Kyoto Japan. Clinical ophtalmology 2011;5:1031-1036
Gutierrez M, Barquet L.A. Caminal J M, Mitjana. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Barcelona Spain. Clinical opthalmology 2008;2(4):787-791
Thapa R. Maharjan N. Paudyal G. Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12 month results. Nepal. Clinical ophtalmology 2012;6:1057-1062.
Yalamanchi S, Flynn H.W. Hemiretinal Vein Occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab. Miami USA. Clinical ophtalmology 2011;5:1509-1513
Demir M. Oba E. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion:12 month result. Turkey. Clinical opthalmology 2011;5:754-749
Mahmood T. Central Retinal Vein Occlusion: current management options. Pak J ophtalmol 2009, vol 25 No1
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States,Europe, Asia, and Australia. Ophthalmology. 2010;117:313–319.
Klein R, Klein BEK, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142:531–539.
Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. ArchOphthalmol. 2008;126:513–518
Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115:47–54.
Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298–306.
Brown DM, Campochiaro PA, Singh RP, et al. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study. Ophthalmology. 2010;117:1124–1133.